Form 8-K · Current report
Target Corporation 8-K, filed Aug 19, 2026
- Filed
- CIK
- 0000027419
- Accession no.
- 0000027419-26-000034
Summary
Target Corporation reported second-quarter 2026 net sales of $26.5 billion, up 5.3% from a year earlier, and GAAP and adjusted EPS of $4.11 versus $2.05, including $1.65 per share from IEEPA tariff refunds. The company raised its full-year 2026 net sales growth guidance to around 5% and its EPS guidance to $9.90–$10.90, with CEO Michael Fiddelke citing momentum and price cuts on more than 10,000 items.
Key points
- Target reported second-quarter 2026 net sales of $26.5 billion, up 5.3%, with comparable sales up 3.8% and comparable traffic up 3.6%.
- Second-quarter GAAP and adjusted EPS was $4.11, compared with $2.05 a year earlier, including $1.65 per share from IEEPA tariff refunds.
- Target updated full-year 2026 guidance to net sales growth around 5% and GAAP and adjusted EPS of $9.90 to $10.90, including second-quarter tariff refund benefits.
- CEO Michael Fiddelke said the results built on first-quarter momentum and noted the company had lowered prices on more than 10,000 frequently purchased items over the past year.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 19, 2026, Target Corporation issued a News Release containing its financial results for the three months ended August 1, 2026. The News Release is attached hereto as Exhibit 99. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99 Target Corporation’s News Release dated August 19, 2026, containing its financial results for the three months ended August 1, 2026. 104 Cover Page Interactive Data File (formatted as inline XBRL). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.